219 related articles for article (PubMed ID: 34593218)
21. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
Griffith C; Zhang S; Mukhopadhyay S
Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
[TBL] [Abstract][Full Text] [Related]
22. Response to RET-Specific Therapy in
Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
[No Abstract] [Full Text] [Related]
23. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
24. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
25. Recent advances in treatment of medullary thyroid carcinoma.
Vezzosi D; Bennet A; Caron P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):147-53. PubMed ID: 17391636
[TBL] [Abstract][Full Text] [Related]
26. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
27. [Refractory thyroid cancers].
Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
[TBL] [Abstract][Full Text] [Related]
28. [Medullary thyroid carcinoma and other rare types of thyroid carcinoma].
Obara T
Nihon Rinsho; 2007 Nov; 65(11):2087-91. PubMed ID: 18018575
[TBL] [Abstract][Full Text] [Related]
29. [Radiation therapy in thyroid cancer].
Sun XS; Guevara N; Fakhry N; Sun SR; Marcy PY; Santini J; Bosset JF; Thariat J
Cancer Radiother; 2013 Jun; 17(3):233-43; quiz 255-6, 258. PubMed ID: 23763764
[TBL] [Abstract][Full Text] [Related]
30. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
31. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
33. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
34. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
35. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
36. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
Torrez M; Braunberger RC; Yilmaz E; Agarwal S
Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
38. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
39. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
40. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
